The News Service
Discoveries in neuroscience
Malaria drug blocks brain conduits, a boon for neuroscience research
A common treatment for malaria shuts down two kinds of connexins, protein “tunnels” that transfer information between nerve cells, according to research conducted at Brown University and Albert Einstein College of Medicine. Published in this week’s online early edition of Proceedings of the National Academy of Sciences, the finding will help scientists plumb the secrets of connexins – crucial electrical conduits found in the brain, heart and other organs.
PROVIDENCE, R.I. — Brown University researchers have discovered that mefloquine, an anti-malarial drug, blocks two gap junction proteins, or connexins, in low doses and with very few side effects in the brains of laboratory mice. The work opens an important door: Connexins found in high concentrations in the brain are believed to play a critical role in movement, vision and memory.
To understand how these communication “tunnels” work, scientists must be able to shut them off. Once those tunnels are disabled, researchers can pinpoint the information that connexins pass between nerve cells and determine how that information affects how the body’s development and function.
A technique already exists to study connexins.
Scientists can remove, or “knock out,” genes that hold the recipe for connexins, then study the results in mice. But the Brown University scientists who worked on the experiment – Barry Connors, professor of neuroscience, and Scott Cruikshank, research associate – said “knockout mice” aren’t a perfect model. As mice – and humans – grow, they can compensate for missing genes by turning other genes on or off and cooking up other protein recipes. These biochemical changes can make it difficult to recognize connexins’ role.
But mefloquine in adult mice precisely and potently blocks connexins called Cx36 and Cx50. There are about 20 kinds of connexins in the brain and eye, as well in organs such as the heart, liver and pancreas. Cx36 is found in the brain; Cx50 is located in the lens. By specifically blocking them, Cruikshank said mefloquine will be a useful tool for electrical synapse study.
“Mefloquine isn’t a magic bullet, but it seems to be better than anything out there,” he said. “It’s a lot more selective, so it has real utility for science.”
Connors said the discovery, detailed in the online early edition of the Proceedings of the National Academy of Sciences for the week of August 2, could shed light on the cause of epilepsy and seizures. Scientists suspect that a Cx36 mutation causes these common neurological conditions, which occur when the messages swapped between synapses get scrambled. Meanwhile, a Cx50 mutation can form cataracts in mice.
“Electrical synapses were only discovered in the neocortex of mammals five years ago,” Connors said, “so they are still a mystery. What do they control? How? When? These are big questions in neuroscience and this drug will help us answer some of them.”
Conducted with scientists at Albert Einstein College of Medicine in New York and funded by the National Institutes of Health, the research offered up an intriguing secondary finding.
In rare cases, mefloquine can cause anxiety, panic attacks, depression and other psychotic side effects. Doctors have never understood why. Connors and Cruikshank said their research may hold the answer: Connexin shut-down in the brain.